During and after this period, neuro-oncological treatment of glioblastomas has progressed, e.g. the advent of chemotherapy with TMZ and CCNU for patients with MGMT promoter-methylated glioblastoma (Herrlinger et al. 2019) as well as the introduction of tumour-treating fields (Stupp et al. 2017). The gene discussed is MGMT; the disease is glioblastoma.